Elevance Health (NYSE:ELV) Now Covered by Evercore

Evercore started coverage on shares of Elevance Health (NYSE:ELV) in a research report released on Wednesday, Marketbeat.com reports. The firm issued an in-line rating and a $345.00 price target on the stock.

A number of other research analysts also recently weighed in on ELV. Mizuho lowered their price objective on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Guggenheim reduced their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Morgan Stanley reduced their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Finally, Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Twelve analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Hold” and an average price target of $385.38.

Elevance Health Stock Up 2.1%

Shares of Elevance Health stock opened at $318.39 on Wednesday. The company has a market cap of $69.94 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 1.65 and a beta of 0.49. The company’s 50 day moving average is $312.51 and its 200 day moving average is $332.18. Elevance Health has a twelve month low of $273.71 and a twelve month high of $444.37. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts anticipate that Elevance Health will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. Elevance Health’s dividend payout ratio is currently 27.39%.

Institutional Trading of Elevance Health

A number of hedge funds and other institutional investors have recently modified their holdings of ELV. Physician Wealth Advisors Inc. increased its stake in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares in the last quarter. Activest Wealth Management increased its stake in shares of Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC increased its stake in shares of Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Elevance Health in the fourth quarter worth $31,000. Finally, Motco increased its stake in shares of Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 77 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a 2.48% Medicare Advantage payment rate for 2027 and officials noted about a 2.5% lift from risk‑adjustment changes—pushing the effective increase closer to ~5% and materially improving managed‑care revenue outlook. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Analysts are responding: Evercore reinstated coverage with an “in‑line” rating and a $345 price target (implying upside vs. recent levels), signaling renewed institutional interest. Elevance Health Reinstated at Inline by Evercore ISI
• Positive Sentiment: Bank of America updated its managed‑care outlook and raised its price target on ELV, supporting upside from improved policy tailwinds. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Positive Sentiment: Several analysts and media pieces frame the CMS decision as a catalyst—some argue ELV is now attractively valued after a large share‑price decline and that technicals/valuation could support a rebound. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
• Neutral Sentiment: Coverage roundup and “top 5” lists highlight ELV as a beneficiary of the rate decision, which may attract rotation into health insurers but doesn’t change longer‑term fundamentals by itself. 5 Stocks That Should Benefit from the 2026 Medicare Advantage Rate Decision
• Neutral Sentiment: Company news items such as leadership changes and an upcoming earnings cycle are being discussed; these are watch‑items that could affect guidance/strategy but are not driving the immediate move. Will Elevance Health’s (ELV) Leadership Shuffle Refocus Its Core Advantage In Government Programs?
• Negative Sentiment: Some analysis reminds investors that ELV has faced structural headwinds (membership declines, higher benefit expense ratios) and has underperformed the market—a 1‑year ~27% slide keeps valuation/recovery risk on the table. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.